The oral solution offers precise dosing, benefiting patients with swallowing difficulties or requiring tailored dosing.

Suboptimal response or treatment failure to standard-dose imatinib are relevant problems in chronic-phase chronic myeloid leukemia patients. Insufficient adherence is one of the main causes of ...

Get detailed information on Imatinib, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

Imkeldi is a new formulation of imatinib approved as a strawberry-flavored, shelf-stable liquid designed to be more appealing ...

Imkeldi is supplied as a strawberry-flavored oral solution in a 140 mL, child-resistant, tamper-evident bottle.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the FDA has approved IMKELDI (imatinib) oral solution, the ...

Imkeldi is supplied as a strawberry-flavored oral solution in a 140mL child resistant tamper-evident bottle. The Food and Drug Administration (FDA) has approved Imkeldi, an oral solution ...

In 2001, a Time Magazine cover story touted Novartis’ targeted leukemia treatment Gleevec (imatinib) as a new kind of “ammunition in the war against cancer.” Along with a picture of the ...

Imatinib oral solution has gained FDA approval for the treatment of some cancers, including certain forms of leukemia.